Because dimerized human epidermal growth factor receptor 2/human epidermal growth factor receptor 3 (HER2/HER3), expressed by ERBB2 and ERBB3, respectively (12), are the tyrosine kinase targets of regorafenib (13), we hypothesize that regorafenib may reverse immunosuppressive tumor microenvironment and synergistically enhance the efficacy of ICIs in patients with ERBB2/ERBB3 mutation or amplification. Here, ERBB2 is linked to neoplasm.